Previous Article | Next Article ![]()
Infect Immun, July 1998, p. 3113-3119, Vol. 66, No. 7
Departments of
Microbiology1 and
Pediatrics,2 University of Texas
Southwestern Medical Center, Dallas, Texas 75235-9048
Received 2 January 1998/Returned for modification 13 February
1998/Accepted 14 April 1998
The UspA surface antigen of Moraxella catarrhalis was
recently shown to be comprised of two different proteins (UspA1 and UspA2) which share an internal region containing 140 amino acids with
93% identity (C. Aebi, I. Maciver, J. L. Latimer, L. D. Cope, M. K. Stevens, S. E. Thomas, G. H. McCracken,
Jr., and E. J. Hansen, Infect. Immun. 65:4367-4377, 1997).
Isogenic uspA1, uspA2, and uspA1
uspA2 mutants were tested in a number of in vitro systems to
determine what effect these mutations, either individually or together,
might exert on the phenotype of M. catarrhalis 035E. Monoclonal antibodies specific for UspA1 or UspA2 were used in an
indirect antibody accessibility assay to prove that both of these
proteins were expressed on the surface of M. catarrhalis. All three mutants grew in vitro at the same rate and
did not exhibit autoagglutination or hemagglutination properties that
were detectably different from those of the wild-type parent strain.
When tested for the ability to adhere to human epithelial
cells, the wild-type parent strain and the uspA2 mutant
readily attached to Chang conjunctival cells. In contrast, the
uspA1 mutant and the uspA1 uspA2 double mutant
both attached to these epithelial cells at a level nearly 2 orders of
magnitude lower than that obtained with the wild-type parent
strain, a result which suggested that expression of UspA1 by
M. catarrhalis is essential for attachment to
these epithelial cells. Both the wild-type parent strain and the
uspA1 mutant were resistant to the bactericidal activity of
normal human serum, whereas the uspA2 mutant and the
uspA1 uspA2 double mutant were readily killed by this
serum. This latter result indicated that the presence of UspA2 is
essential for expression of serum resistance by M. catarrhalis.
Moraxella catarrhalis is
an important pathogen of the respiratory tract of both children and
adults. This unencapsulated, gram-negative organism accounts for up to
20% of cases of acute bacterial otitis media (6, 7, 17, 37)
and is associated with approximately one-third of infectious
exacerbations of chronic obstructive pulmonary disease in adults
(14, 24, 40, 44). As a consequence of its emerging medical
importance, M. catarrhalis has become the focus of
research efforts aimed at elucidating its interaction with the human
host and at developing strategies for a vaccine to protect against this
pathogen (3, 15-18, 20-22, 36, 39, 47).
Efforts to identify potential vaccine candidates among the surface
antigens of M. catarrhalis have focused primarily on
the outer membrane proteins of this organism. In M. catarrhalis, outer membrane protein profiles examined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) display
remarkably little strain-specific variability (5, 41). Some
of these outer membrane proteins, especially CopB (outer membrane
protein B2 [OMP B2]) (2, 8, 26, 28, 51), OMP CD (32,
42), and the UspA antigen (high-molecular-weight outer membrane
protein [HMW-OMP]) (27, 35), which consists of two related
proteins, UspA1 and UspA2 (1), have been characterized in
some detail. CopB and OMP CD, as well as either or both UspA1 and
UspA2, have been shown to induce the synthesis of antibodies that are
biologically active against M. catarrhalis (11,
26, 27, 58).
The UspA1 and UspA2 proteins are of particular interest because of
their unusual characteristics. In M. catarrhalis 035E, the uspA1 and uspA2 genes encode predicted
proteins of 88 and 62 kDa, respectively (1). In SDS-PAGE,
the native forms of these two proteins apparently form oligomers or
aggregates, each of which migrates in SDS-PAGE with an apparent
molecular weight of greater than 250,000. Apparently monomeric forms of
these proteins can be detected in Western blot analysis as minor bands
of approximately 120 kDa (UspA1) and 85 kDa (UspA2) (1). The
amino acid sequences of UspA1 and UspA2 are 43% identical, but an
internal region in each protein contains 140 amino acids where the
level of identity is 93%. This latter region contains an epitope
that is present in both UspA1 and UspA2 and which is defined by its
reactivity with the monoclonal antibody (MAb) 17C7 (1). This
epitope is present in all disease-associated isolates of
M. catarrhalis tested to date and induces the
synthesis of antibodies that, when used to passively immunize mice,
enhanced the elimination of M. catarrhalis in a
pulmonary clearance model (27). Equally important, the very
high molecular weight UspA antigen composed of UspA1 and UspA2 has been
shown to be a target for antibodies present in convalescent sera of
patients recovering from M. catarrhalis infections (13, 25, 27), indicating that one or both of these proteins are expressed in vivo.
To assess and differentiate functional characteristics of the UspA1 and
UspA2 proteins, we constructed a set of isogenic mutants of
M. catarrhalis 035E that lacked the ability to express
UspA1 or UspA2 or both of these proteins. These mutants were
compared to the wild-type strain in a number of in vitro systems,
including assessment of their abilities to adhere to
human epithelial cells and to resist killing by normal
human serum.
Bacterial strains, plasmids, and growth conditions.
The
bacterial strains and plasmids used in this study are listed in Table
1. M. catarrhalis strains
were routinely grown at 37°C on brain heart infusion (BHI) agar
plates (Difco Laboratories, Detroit, Mich.) in an atmosphere of 95%
air-5% CO2 supplemented, when necessary, with kanamycin
(20 µg/ml) (Sigma Chemical Co., St. Louis, Mo.) or chloramphenicol
(0.5 µg/ml) (Sigma); in some cases, cells were grown in BHI broth.
The BHI broth used to grow M. catarrhalis cells for
attachment assays was sterilized by filtration. Escherichia
coli strains were cultured on Luria-Bertani agar plates (38) supplemented, when necessary, with ampicillin (100 µg/ml), kanamycin (30 µg/ml), or chloramphenicol (30 µg/ml).
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Phenotypic Effect of Isogenic uspA1 and
uspA2 Mutations on Moraxella
catarrhalis 035E

![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
TABLE 1.
Bacterial strains and plasmids used in this study
Characterization of outer membrane proteins. Outer membrane vesicles of M. catarrhalis strains were prepared as described previously (43, 45). Proteins present in these preparations were resolved by SDS-PAGE and detected by staining with Coomassie blue or by Western blot analysis as described elsewhere (26).
MAbs. MAb 17C7 is a murine immunoglobulin G (IgG) antibody that reacts with a conserved epitope of both UspA1 and UspA2 from M. catarrhalis 035E (1). To produce MAbs individually specific for UspA1 and UspA2, mice were immunized by intraperitoneal injection with 50 µg of either purified UspA1 or purified UspA2 from strain 035E (40a) suspended in 50% (vol/vol) Freund's complete adjuvant (Difco). One month later, the mice received an intraperitoneal injection with 25 µg of the appropriate protein suspended in 50% (vol/vol) Freund's incomplete adjuvant (Difco). Approximately 2 weeks later, the mice were injected intravenously with 25 µg of the purified protein. Three days later, the mice were euthanized and their spleens were removed for use in the hybridoma fusion protocol (48). Hybridoma culture supernatants were screened for the presence of UspA1- or UspA2-specific MAbs, using purified UspA1 or UspA2 as antigen in an enzyme-linked immunosorbent assay. The IgG1 MAb 11A6 was shown to be specific for UspA1, and the IgG1 MAb 17H4 was shown to be specific for UspA2. MAb 3F12, an IgG MAb specific for the major outer membrane protein of Haemophilus ducreyi (34), was used as a negative control in the indirect antibody accessibility assay. These MAbs were used in the form of hybridoma culture supernatant fluid in both the indirect antibody accessibility assay and the colony blot radioimmunoassay (23). MAbs 17C7 and 11A6 were purified with protein G-Sepharose 4 Fast Flow (Amersham Pharmacia Biotech, Piscataway, N.J.) for use in attachment inhibition assays.
Mutant construction method.
The 1.3-kb chloramphenicol
resistance (cat) cartridge was prepared by excision (using
BamHI) from pUC
ECAT (kindly provided by Bruce A. Green,
Wyeth-Lederle Vaccines). The cat cartridge was subsequently
ligated into BglII restriction sites located in the
mid-portion of the cloned segment from the uspA1 gene in pUSPA1 (1); after transformation of competent E. coli DH5
cells, recombinant clones were identified by selection
on solidified media containing chloramphenicol.
Transformation of M. catarrhalis. The electroporation method used for transformation of M. catarrhalis 035E has been described in detail elsewhere (28). In this study, M. catarrhalis cells were electroporated with 5 µg of linear DNA (a PCR product containing the truncated uspA1 gene with the cat cartridge insertion) in 5 µl of water.
Southern blot analysis. Chromosomal DNA purified from wild-type and mutant M. catarrhalis strains was digested with either PvuII or HindIII (New England Biolabs), and Southern blot analysis was performed as described previously (50). Double-stranded DNA probes were labeled with P by using a Random Primed DNA labeling kit (Boehringer Mannheim, Indianapolis, Ind.).
Indirect antibody accessibility assay. Overnight BHI broth cultures of M. catarrhalis 035E and its isogenic mutants were diluted in phosphate buffered saline (PBS) containing 10% (vol/vol) fetal bovine serum and 0.025% (wt/vol) sodium azide (PBS-FBS-A) to a density of 110 Klett units (ca. 5 × 108 CFU/ml) as measured with a Klett-Summerson colorimeter (Klett Manufacturing Co., New York, N.Y.). Portions (100 µl) of this suspension were added to 1 ml of hybridoma culture supernatant. After incubation at 4°C for 1 h with gentle agitation, the bacterial cells were washed once and suspended in 1 ml of PBS-FBS-A. Affinity-purified goat anti-mouse immunoglobulin, radiolabeled with 125I to a specific activity of 108 cpm per µg, was added and the mixture was incubated for 1 h at 4°C with gentle agitation. The cells were then washed four times with 1 ml of PBS-FBS-A, suspended in 500 µl of triple detergent (26), and transferred to glass tubes. The radioactivity present in each sample was measured by using a gamma radiation counter.
Autoagglutination and hemagglutination assays. The ability of M. catarrhalis strains to autoagglutinate was assessed by using bacterial cells grown overnight on a BHI agar plate. These cells were resuspended in PBS to a turbidity of 400 Klett units in a glass tube and subsequently allowed to stand at room temperature for 10 min, at which time the turbidity of this suspension was again determined. Rapid and slow autoagglutination were defined as turbidities of less than and greater than 200 Klett units, respectively, after 10 min. The hemagglutination slide assay using heparinized human blood group O Rh+ erythrocytes was performed as previously described (52).
Serum bactericidal assay. Complement-sufficient normal adult human serum was prepared by standard methods. Complement inactivation was achieved by heating the serum for 30 min at 56°C. An M. catarrhalis broth culture in early logarithmic phase was diluted in Veronal-buffered saline containing 0.10% (wt/vol) gelatin to a concentration of 1 × 105 CFU/ml, and 20-µl portions were added to 20 µl of native or heat-inactivated normal human serum together with 160 µl of Veronal-buffered saline containing 5 mM MgCl2 and 1.5 mM CaCl2. This mixture was incubated at 37°C in a stationary water bath. At time 0 and at 15 and 30 min, duplicate 10-µl aliquots were removed, suspended in 75 µl of BHI broth, and spread onto prewarmed BHI agar plates.
Adherence assay. A method used to measure adherence of Haemophilus influenzae to Chang conjunctival cells in vitro (55) was adapted for use with M. catarrhalis. Briefly, 2 × 105 to 3 × 105 HEp-2 cells (ATCC CCL 23) or Chang conjunctival cells (ATCC CCL 20.2) were seeded into each well of a 24-well tissue culture plate (Corning-Costar) and incubated for 24 h before use. A 0.3-ml volume from an antibiotic-free overnight culture of M. catarrhalis was inoculated into 10 ml of fresh BHI medium lacking antibiotics, and this culture was subsequently allowed to grow to a density of approximately 5 × 108 CFU/ml (120 Klett units) with shaking in a gyratory water bath. The culture was harvested by centrifugation at 6,000 × g at 4 to 8°C for 10 min. The supernatant was discarded, and a Pasteur pipette was used to gently resuspend the bacterial cells in 5 ml of pH 7.4 PBS or PBS containing 0.15% (wt/vol) gelatin (PBS-G). The bacterial cells were centrifuged again, and this final pellet was gently resuspended in 6 to 8 ml of PBS or PBS-G.
Portions (25 µl containing 107 CFU) of this suspension were inoculated in duplicate into the wells of a 24-well tissue culture plate containing monolayers of HEp-2 or Chang cells. For attachment inhibition assays, the bacterial cells were incubated with various concentrations of purified MAbs for 30 min at 37°C immediately prior to addition of these bacterial cells to the monolayers. These tissue culture plates were centrifuged for 5 min at 165 × g and then incubated for 30 min at 37°C. Nonadherent bacteria were removed by rinsing the wells gently five times with PBS or PBS-G, and the epithelial cells were then released from the plastic support by adding 200 µl of PBS containing 0.05% trypsin and 0.02% EDTA. This cell suspension was serially diluted in PBS or PBS-G and spread onto BHI plates to determine the number of viable M. catarrhalis present. Adherence was expressed as the percentage of bacteria attached to the human cells relative to the original inoculum added to the well.| |
RESULTS |
|---|
|
|
|---|
Construction of an isogenic M. catarrhalis mutant lacking expression of both UspA1 and UspA2. Construction of M. catarrhalis mutants lacking the ability to express either UspA1 (mutant strain 035E.1) or UspA2 (mutant strain 035E.2) has been described elsewhere (1). For constructing a double mutant that lacked expression of both UspA1 and UspA2, the 0.6-kb BglII fragment within the incomplete uspA1 open reading frame of pUSPA1 (1) was replaced with a cat cartridge, yielding the recombinant plasmid pUSPA1CAT. Oligonucleotide primers (5'-CGGGATCCGTGAAGAAAAATGCCGCAGGT-3' and 5'-CGGGATCCCGTCGCAAGCCGATTG-3') were used in PCR to amplify the 3.2-kb insert of pUSPA1CAT; this PCR product was used to electroporate the kanamycin-resistant uspA2 mutant 035E.2. Southern blot analysis was used to prove that a chloramphenicol- and kanamycin-resistant transformant (strain 035E.12) derived from this experiment was a uspA1 uspA2 double mutant (data not shown).
Characterization of selected proteins expressed by the wild-type and mutant M. catarrhalis strains. Proteins present in outer membrane vesicles extracted from the wild-type strain and these three mutant strains were resolved by SDS-PAGE and either stained with Coomassie blue (Fig. 1A) or probed with MAb 17C7 in Western blot analysis (Fig. 1B). The wild-type parent strain 035E possessed a very high molecular weight band detectable by Coomassie blue staining (Fig. 1A, lane 1) that was also similarly abundant in the uspA1 mutant 035E.1 (Fig. 1A, lane 2). The uspA2 mutant 035E.2 (Fig. 1A, lane 3) had a much reduced level of expression of a band in this same region of the gel; this band was not visible in the uspA1 uspA2 double mutant 035E.12 (Fig. 1A, lane 4).
|
Binding of UspA1- and UspA2-specific MAbs to whole cells of the wild-type and mutant strains. The indirect antibody accessibility assay was used to determine whether both UspA1 and UspA2 are exposed on the surface of M. catarrhalis and accessible to antibody. MAbs 11A6 and 17H4, specific for UspA1 and UspA2, respectively, were produced for use in this assay. The specificity of each of these MAbs was first confirmed in the colony blot radioimmunoassay where MAb 11A6 bound the wild-type strain 035E and the uspA2 mutant but did not bind the uspA1 mutant 035E.1 or the uspA1 uspA2 mutant 035E.12 (Fig. 2A). MAb 17H4 bound the wild-type strain 035E and the uspA1 mutant 035E.1 but did not react with the uspA2 mutant 035E.2 or with the double mutant 035E.12 (Fig. 2A). Both of these MAbs bound to the surface of whole cells of the wild-type strain 035E in the indirect antibody accessibility assay (Fig. 2B), a result which indicated that both UspA1 and UspA2 are exposed on the surface of M. catarrhalis 035E. In this same assay, each MAb bound only to the mutant strain that expressed its homologous antigen (e.g., the UspA1-specific MAb 11A6 bound to whole cells of the uspA2 mutant 035E.2) (Fig. 2B). Neither MAb bound to cells of the uspA1 uspA2 mutant 035E.12 (Fig. 2B).
|
Characterization of the growth, autoagglutination, and hemagglutination properties of the wild-type and mutant strains. The colony morphology of these three mutant strains grown on BHI agar plates did not differ from that of the wild-type parent strain (data not shown). Similarly, the rates and extents of growth of all four of these strains in BHI broth were very similar if not identical (Fig. 3). In an autoagglutination assay performed as described in Materials and Methods, all four strains exhibited the same, relatively low rate of autoagglutination (data not shown). Finally, there was no detectable difference between the wild-type parent and the three mutants in a hemagglutination assay using human erythrocytes (52). Control hemagglutination experiments were performed with a pair of M. catarrhalis isolates (strains P-44 and P-48) previously characterized as having rapid and slow rates, respectively, of hemagglutination (52).
|
Effect of the uspA1 and uspA2 mutations on the ability of M. catarrhalis to adhere to human cells. Preliminary experiments revealed that the wild-type M. catarrhalis strain 035E adhered readily to HeLa cells, HEp-2 cells, and Chang conjunctival cells in vitro (data not shown). To determine whether lack of expression of UspA1 or UspA2 affected this adherence ability, the wild-type strain and the three mutant strains were first used in an attachment assay with HEp-2 cells. In this set of experiments, PBS was used to wash the HEp-2 cell monolayers and as the diluent for serial dilution of the trypsinized HEp-2 cell monolayer at the completion of the assay. The wild-type strain and the uspA2 mutant 035E.2 exhibited similar levels of attachment to HEp-2 monolayers (Table 2). The uspA1 mutant 035E.1, however, was less able to adhere to these HEp-2 cells; lack of expression of UspA1 reduced the level of attachment approximately sixfold (Table 2). The uspA1 uspA2 double mutant 035E.12 exhibited a similarly reduced level of attachment (Table 2).
|
Effect of the uspA1 and uspA2 mutations on serum resistance of M. catarrhalis. Because the M. catarrhalis UspA2 protein was previously found to resemble most closely the YadA outer membrane protein involved in serum resistance of pathogenic Yersinia species (1), it was appropriate to determine whether UspA2 might play the same functional role in M. catarrhalis. Similar to the majority of disease isolates of M. catarrhalis (29, 30, 57), the wild-type strain 035E was resistant to killing by normal human serum in vitro (28). To examine the effect of the lack of expression of UspA1 or UspA2 on serum resistance, the wild-type strain and the three mutant strains were tested in a serum bactericidal assay. Both the wild-type strain and the uspA1 mutant 035E.1 were able to grow in the presence of normal human serum (Fig. 4), indicating that lack of expression of UspA1 did not adversely affect the ability of strain 035E.1 to resist killing by normal human serum. However, both the uspA2 mutant 035E.2 and the uspA1 uspA2 double mutant 035E.12, having in common the lack of expression of UspA2, were readily killed by normal human serum (Fig. 4). Heat-based inactivation of the complement system present in this normal human serum eliminated the ability of this serum to kill these latter two mutants (Fig. 4).
|
| |
DISCUSSION |
|---|
|
|
|---|
Lack of the ability to express UspA1 or UspA2 or both of these proteins had little or no discernible effect on the ability of the respective M. catarrhalis mutants to grow in vitro (Fig. 3). Similarly, it would now appear that UspA1 and UspA2 are not involved in either autoagglutination or hemagglutination in strain 035E because lack of expression of either or both of these macromolecules did not affect the autoagglutination or hemagglutination properties of strain 035E (data not shown). The ability of some M. catarrhalis strains to hemagglutinate may be due to expression of a 200-kDa protein recently described by Fitzgerald et al. (19). In this context, it should be noted that strain 035E apparently does not express this 200-kDa protein and both autoagglutinates and hemagglutinates relatively slowly.
The production of MAbs individually specific for UspA1 and UspA2 permitted unequivocal demonstration of the fact that both of these macromolecules are exposed on the surface of M. catarrhalis 035E (Fig. 2B). Furthermore, the relative level of binding of the UspA1- and UspA2-reactive MAb 17C7 by proteins in outer membrane vesicles of the uspA1 and uspA2 mutants in Western blot analysis (Fig. 1B, lanes 2 and 3) suggested that there is likely more UspA2 than UspA1 present in strain 035E. Subsequent analyses performed in the present study revealed that UspA1 and UspA2 differ by more than just their relative abundance in M. catarrhalis. Specifically, mutations that independently eliminated expression of these two macromolecules had profound effects on at least two different phenotypic traits (adherence ability and serum resistance) of M. catarrhalis 035E.
The similarity between UspA1 and the H. influenzae adhesins encoded by the hsf (54) and hia genes (4) prompted investigation of the possibility that UspA1 is functionally involved in the ability of M. catarrhalis to attach to human epithelial cells. Initial experiments utilizing HeLa, HEp-2, and Chang conjunctival cells revealed that the M. catarrhalis wild-type strain 035E bound readily to these cell lines (data not shown). Additional testing involving the uspA1, uspA2, and uspA1 uspA2 mutants derived from strain 035E revealed that both the uspA1 and uspA1 uspA2 mutants did not exhibit wild-type levels of attachment to HEp-2 cells in vitro (Table 2). Further investigation showed that the uspA1 mutant adhered to Chang conjunctival cells at a level nearly 2 orders of magnitude lower than that obtained with the wild-type parent strain. In contrast, the uspA2 mutant adhered to Chang cells at wild-type levels.
It remains to be determined whether UspA1 itself is an adhesin or whether expression of UspA1 is simply required for proper expression or conformation of another macromolecule which itself is the true adhesin. Bearing in mind the complex situation involving adhesins which are positioned in the tips of the pili of gram-negative bacteria such as Neisseria gonorrhoeae (49), it is premature to conclude that UspA1 binds directly to the human epithelial cells used in the present study. A preliminary report that antiserum directed against purified UspA inhibited attachment of M. catarrhalis to human epithelial cells was published prior to the discovery that there are two UspA proteins expressed by M. catarrhalis (10). Whether this polyclonal antibody bound to UspA1 or UspA2 or both proteins is relevant to correct interpretation of the functional basis for this inhibitory effect. In addition, another laboratory has recently reported that the CD protein of M. catarrhalis will bind highly purified human middle ear mucin (47), a finding which reinforces the likelihood that M. catarrhalis possesses multiple systems for binding host factors. Finally, it must be noted that there clearly are many differences between Chang cells and the epithelium of the upper respiratory tract. Investigation of the attachment ability of the uspA1 mutant in human nasopharyngeal organ culture (53) would provide a more stringent test of the role of UspA1 in the attachment process.
The similarity of the UspA2 protein to the YadA protein expressed by pathogenic Yersinia species also had predictive value regarding the involvement of this M. catarrhalis protein in protecting this organism against killing by normal human serum. YadA has been shown to confer serum resistance on Y. enterocolitica by promoting the fixation of factor H (12), which in turn leads to the degradation of C3b deposited on the bacterial cell surface and prevention of formation of the membrane attack complex (46), in a manner similar to that observed with the M protein of Streptococcus pyogenes (31). When the set of three isogenic M. catarrhalis mutants was incubated in complement-sufficient normal human serum, the uspA2 mutant and the uspA1 uspA2 mutant were both readily killed in this serum (Fig. 4). In contrast, the uspA1 mutant resisted killing by this serum as effectively as did the wild-type parent strain (Fig. 4).
It is known that isolates of M. catarrhalis can be divided into those that are sensitive to the bactericidal activity of normal human serum and those that are resistant to this killing (9, 30, 33, 56, 57). Moreover, one group has suggested that complement resistance is a virulence factor for M. catarrhalis, based on their finding that the majority of disease isolates of M. catarrhalis exhibit some degree of complement resistance (30). A preliminary study by Verduin et al. (56) suggested that the HMW-OMP of M. catarrhalis, which is now known to be identical to either UspA1 or UspA2, is responsible for this serum resistance exhibited by disease isolates of M. catarrhalis. Regardless of whether the HMW-OMP is UspA1 or UspA2, the fact remains that lack of expression of UspA2 in an isogenic uspA2 mutant rendered the serum-resistant wild-type parent strain exquisitely sensitive to killing by this serum. It should also be noted that the available data do not allow determination of whether UspA2 exerts a direct or indirect effect on serum resistance of M. catarrhalis. The existence of such a causal relationship remains to be established and must be pursued carefully, especially because a previous study from our own laboratory has shown that lack of expression of the CopB outer membrane protein, which is likely involved in some transport process, resulted in loss of serum resistance by M. catarrhalis (28).
In conclusion, mutations in the uspA1 and uspA2 genes of M. catarrhalis 035E affected two different phenotypic traits of this pathogen. Southern blot analysis has suggested that disease isolates of M. catarrhalis likely possess both uspA1 and uspA2 genes (1), and future studies will be designed to investigate whether lack of expression of UspA1 or UspA2 has similar effects on other strains of this pathogen. Whether both of these genes are present and expressed in all strains of M. catarrhalis also remains to be determined. This is especially important with regard to isolates of M. catarrhalis obtained from healthy children (i.e., nasopharyngeal carriage isolates). Whether UspA1 or UspA2 could be required for expression of some other capability essential to the ability of M. catarrhalis to colonize the upper respiratory tract or to the production of disease remains to be determined.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by Public Health Service grant AI36344 and by Texas Advanced Technology Program award 003660-087 to E.J.H. C.A. was supported by a research grant for young investigators from Novartis AG, Basel, Switzerland.
We thank Steven Berk for providing several isolates of M. catarrhalis. We also acknowledge the generosity of Bruce A. Green and John McMichael in providing the cat cartridge and purified UspA1 and UspA2 from M. catarrhalis 035E, respectively.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Hamon Building, NA6.200, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75235-9048. Phone: (214) 648-5974. Fax: (214) 648-5905. E-mail: hansen01{at}utsw.swmed.edu.
Present address: Department of Pediatrics, University of Bern,
Inselspital, CH-3010 Bern, Switzerland.
Editor: J. G. Cannon
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Aebi, C., I. Maciver, J. L. Latimer, L. D. Cope, M. K. Stevens, S. E. Thomas, G. H. McCracken, Jr., and E. J. Hansen. 1997. A protective epitope of Moraxella catarrhalis is encoded by two different genes. Infect. Immun. 65:4367-4377[Abstract]. |
| 2. | Aebi, C., B. Stone, M. Beucher, L. D. Cope, I. Maciver, S. E. Thomas, G. H. McCracken, Jr., P. F. Sparling, and E. J. Hansen. 1996. Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin. Infect. Immun. 64:2024-2030[Abstract]. |
| 3. | Ahmed, K., K. Matsumoto, N. Rikitomi, and T. Nagatake. 1996. Attachment of Moraxella catarrhalis to pharyngeal epithelial cells is mediated by a glycosphingolipid receptor. FEMS Microbiol. Lett. 135:305-309[Medline]. |
| 4. | Barenkamp, S. J., and J. W. St. Geme, III. 1996. Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable Haemophilus influenzae. Mol. Microbiol. 19:1215-1223[Medline]. |
| 5. | Bartos, L. C., and T. F. Murphy. 1988. Comparison of the outer membrane proteins of 50 strains of Branhamella catarrhalis. J. Infect. Dis. 158:761-765[Medline]. |
| 6. | Bluestone, C. D. 1986. Otitis media and sinusitis in children: role of Branhamella catarrhalis. Drugs 31(Suppl. 3):132-141. |
| 7. | Bluestone, C. D., J. S. Stephenson, and L. M. Martin. 1992. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11:S7-S11[Medline]. |
| 8. |
Campagnari, A. A.,
K. L. Shanks, and D. W. Dyer.
1994.
Growth of Moraxella catarrhalis with human transferrin and lactoferrin: expression of iron-repressible proteins without siderophore production.
Infect. Immun.
62:4909-4914 |
| 9. | Chapman, A. J., Jr., D. M. Musher, S. Jonsson, J. E. Clarridge, and R. J. Wallace, Jr. 1985. Development of bacterial antibody during Branhamella catarrhalis infection. J. Infect. Dis. 151:878-882[Medline]. |
| 10. | Chen, D., J. McMichael, K. Vandermeid, D. Hahn, R. Smith, J. Eldridge, and J. Cowell. 1995. Antibodies to the UspA outer membrane protein of Moraxella catarrhalis block bacterial attachment in vitro and are protective in a murine pulmonary challenge model, abstr. E-53, p. 290. In Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C. |
| 11. | Chen, D., J. C. McMichael, K. R. van der Meid, D. Hahn, T. Mininni, J. Cowell, and J. Eldridge. 1996. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64:1900-1905[Abstract]. |
| 12. |
China, B.,
M.-P. Sory,
B. T. N'Guyen,
M. de Bruyere, and G. R. Cornelis.
1993.
Role of YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules.
Infect. Immun.
61:3129-3136 |
| 13. | Christensen, J. J., J. Renneberg, B. Bruun, and A. Forsgren. 1995. Serum antibody response to proteins of Moraxella (Branhamella) catarrhalis in patients with lower respiratory tract infection. Clin. Diagn. Lab. Immunol. 2:14-17[Abstract]. |
| 14. | Davies, B. I., and F. P. V. Maesen. 1988. The epidemiology of respiratory tract pathogens in Southern Netherlands. Eur. Respir. J. 1:415-420[Abstract]. |
| 15. | Faden, H. 1995. Comparison of the local immune response to nontypeable Haemophilus influenzae (nHI) and Moraxella catarrhalis (MC) during otitis media, p. 733-736. In J. Mestecky, et al. (ed.), Advances in mucosal immunology. Plenum Press, New York, N.Y. |
| 16. | Faden, H., L. Duffy, R. Wasielewski, J. Wolf, D. Krystofik, Y. Tung, and Tonawanda/Williamsburg Pediatrics. 1997. Relationship between nasopharyngeal colonization and the development of otitis media in children. J. Infect. Dis. 175:1440-1445[Medline]. |
| 17. | Faden, H., Y. Harabuchi, J. J. Hong, and Tonawanda/Williamsburg Pediatrics. 1994. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J. Infect. Dis. 169:1312-1317[Medline]. |
| 18. |
Faden, H. S.,
J. J. Hong, and T. F. Murphy.
1992.
Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media.
Infect. Immun.
60:3824-3829 |
| 19. | Fitzgerald, M., R. Mulcahy, S. Murphy, C. Keane, D. Coakley, and T. Scott. 1997. A 200 kDa protein is associated with haemagglutinating isolates of Moraxella (Branhaemella) catarrhalis. FEMS Immunol. Med. Microbiol. 18:209-216[Medline]. |
| 20. | Goldblatt, D., G. K. Scadding, V. J. Lund, A. M. Wade, M. W. Turner, and J. P. Pandey. 1994. Association of Gm allotypes with the antibody response to the outer membrane proteins of a common upper respiratory tract organism, Moraxella catarrhalis. J. Immunol. 153:5316-5320[Abstract]. |
| 21. | Goldblatt, D., N. D. Seymour, R. J. Levinsky, and M. W. Turner. 1990. An enzyme-linked immunosorbent assay for the determination of human IgG subclass antibodies directed against Branhamella catarrhalis. J. Immunol. Methods 128:219-225[Medline]. |
| 22. | Goldblatt, D., M. W. Turner, and R. J. Levinsky. 1990. Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. J. Infect. Dis. 162:1128-1135[Medline]. |
| 23. |
Gulig, P. A.,
C. C. Patrick,
L. Hermanstorfer,
G. H. McCracken, Jr., and E. J. Hansen.
1987.
Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b.
Infect. Immun.
55:513-520 |
| 24. | Hager, H., A. Verghese, S. Alvarez, and S. L. Berk. 1987. Branhamella catarrhalis respiratory infections. Rev. Infect. Dis. 9:1140-1149[Medline]. |
| 25. | Helminen, M. E., R. Beach, I. Maciver, G. P. Jarosik, E. J. Hansen, and M. Leinonen. 1995. Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay. Clin. Diagn. Lab. Immunol. 2:35-39[Abstract]. |
| 26. |
Helminen, M. E.,
I. Maciver,
J. L. Latimer,
L. D. Cope,
G. H. McCracken, Jr., and E. J. Hansen.
1993.
A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.
Infect. Immun.
61:2003-2010 |
| 27. | Helminen, M. E., I. Maciver, J. L. Latimer, J. Klesney-Tait, L. D. Cope, M. M. Paris, G. H. McCracken, Jr., and E. J. Hansen. 1994. A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies. J. Infect. Dis. 170:867-872[Medline]. |
| 28. | Helminen, M. E., I. Maciver, J. L. Latimer, S. R. Lumbley, L. D. Cope, G. H. McCracken, Jr., and E. J. Hansen. 1993. A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival of this organism in vivo. J. Infect. Dis. 168:1194-1201[Medline]. |
| 29. | Hol, C., C. M. Verduin, E. van Dijke, J. Verhoef, and H. van Dijk. 1993. Complement resistance in Branhamella (Moraxella) catarrhalis. Lancet 341:1281[Medline]. |
| 30. | Hol, C., C. M. Verduin, E. E. A. Van Dijke, J. Verhoef, A. Fleer, and H. van Dijk. 1995. Complement resistance is a virulence factor of Branhamella (Moraxella) catarrhalis. FEMS Immunol. Med. Microbiol. 11:207-212[Medline]. |
| 31. |
Horstmann, R. D.,
H. J. Sievertsen,
J. Knobloch, and V. A. Fischetti.
1988.
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.
Proc. Natl. Acad. Sci. USA
85:1657-1661 |
| 32. |
Hsiao, C. B.,
S. Sethi, and T. F. Murphy.
1995.
Outer membrane protein CD of Branhamella catarrhalis sequence conservation in stains recovered from the human respiratory tract.
Microb. Pathog.
19:215-225[Medline].
|
| 33. | Jordan, K. L., S. H. Berk, and S. L. Berk. 1990. A comparison of serum bactericidal activity and phenotypic characteristics of bacteremic, pneumonia-causing strains, and colonizing strains of Branhamella catarrhalis. Am. J. Med. 88(Suppl. 5A):28S-32S. |
| 34. |
Klesney-Tait, J.,
T. J. Hiltke,
S. M. Spinola,
J. D. Radolf, and E. J. Hansen.
1997.
The major outer membrane protein of Haemophilus ducreyi consists of two OmpA homologs.
J. Bacteriol.
179:1764-1773 |
| 35. |
Klingman, K. L., and T. F. Murphy.
1994.
Purification and characterization of a high-molecular-weight outer membrane protein of Moraxella (Branhamella) catarrhalis.
Infect. Immun.
62:1150-1155 |
| 36. | Klingman, K. L., A. Pye, T. F. Murphy, and S. L. Hill. 1995. Dynamics of respiratory tract colonization by Branhamella catarrhalis in bronchiectasis. Am. J. Respir. Crit. Care Med. 152:1072-1078[Abstract]. |
| 37. | Kovatch, A. L., E. R. Wald, and R. H. Michaels. 1983. Beta-lactamase-producing Branhamella catarrhalis causing otitis media in children. J. Pediatr. 102:261-264[Medline]. |
| 38. | Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 39. | Mathers, A. E., D. Goldblatt, C. Aebi, R.-H. Yu, A. B. Schryvers, and E. J. Hansen. 1997. Characterization of an outer membrane protein of Moraxella catarrhalis. FEMS Immunol. Med. Microbiol. 19:231-236[Medline]. |
| 40. | McLeod, D. T., F. Ahmad, S. Capewell, M. J. Croughan, M. A. Calder, and A. Seaton. 1986. Increase in bronchopulmonary infection due to Branhamella catarrhalis. Br. Med. J. 292:1103-1105. |
| 40a. | McMichael, J., et al. Submitted for publication. |
| 41. | Murphy, T. F. 1989. The surface of Branhamella catarrhalis: a systemic approach to the surface antigens of an emerging pathogen. Pediatr. Infect. Dis. J. 8:S75-S77[Medline]. |
| 42. | Murphy, T. F., C. Kirkham, and A. J. Lesse. 1993. The major heat-modifiable outer membrane protein CD is highly conserved among strains of Branhamella catarrhalis. Mol. Microbiol. 10:87-97[Medline]. |
| 43. | Murphy, T. F., and M. R. Loeb. 1989. Isolation of the outer membrane of Branhamella catarrhalis. Microb. Pathog. 6:159-174[Medline]. |
| 44. |
Nicotra, B.,
M. Rivera,
J. I. Liman, and R. J. Wallace.
1986.
Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease.
Arch. Intern. Med.
146:890-893 |
| 45. |
Patrick, C. C.,
A. Kimura,
M. A. Jackson,
L. Hermanstorfer,
A. Hood,
G. H. McCracken, Jr., and E. J. Hansen.
1987.
Antigenic characterization of the oligosaccharide portion of the lipooligosaccharide of nontypable Haemophilus influenzae.
Infect. Immun.
55:2902-2911 |
| 46. |
Pilz, D.,
T. Vocke,
J. Heesemann, and V. Brade.
1992.
Mechanism of YadA-mediated serum resistance of Yersinia enterocolitica serotype O3.
Infect. Immun.
60:189-195 |
| 47. | Reddy, M. S., T. F. Murphy, H. S. Faden, and J. M. Bernstein. 1997. Middle ear mucin glycoprotein; purification and interaction with nontypeable Haemophilus influenzae and Moraxella catarrhalis. Otolaryngol. Head Neck Surg. 116:175-180[Medline]. |
| 48. |
Robertson, S. M.,
C. F. Frisch,
P. A. Gulig,
J. R. Kettman,
K. H. Johnston, and E. J. Hansen.
1982.
Monoclonal antibodies directed against a cell surface-exposed outer membrane protein of Haemophilus influenzae type b.
Infect. Immun.
36:80-88 |
| 49. | Rudel, T., I. Scheurerpflug, and T. F. Meyer. 1995. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. Nature 373:357-359[Medline]. |
| 50. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 51. | Sethi, S., J. M. Surface, and T. F. Murphy. 1997. Antigenic heterogeneity and molecular analysis of CopB of Moraxella (Branhamella) catarrhalis. Infect. Immun. 65:3666-3671[Abstract]. |
| 52. |
Soto-Hernandez, J. L.,
S. Holtsclaw-Berk,
L. M. Harvill, and S. L. Berk.
1989.
Phenotypic characteristics of Branhamella catarrhalis strains.
J. Clin. Microbiol.
27:903-908 |
| 53. | Stephens, D. S., and M. M. Farley. 1991. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev. Infect. Dis. 13:22-33[Medline]. |
| 54. |
St. Geme, J. W., III,
D. Cutter, and S. J. Barenkamp.
1996.
Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils.
J. Bacteriol.
178:6281-6287 |
| 55. |
St. Geme, J. W., III, and S. Falkow.
1990.
Haemophilus influenzae adheres to and enters cultured human epithelial cells.
Infect. Immun.
58:4036-4044 |
| 56. | Verduin, C. M., H. J. Bootsma, C. Hol, A. Fleer, M. Jansze, K. L. Klingman, T. F. Murphy, and H. van Dijk. 1995. Complement resistance in Moraxella (Branhamella) catarrhalis is mediated by a high-molecular-weight outer membrane protein (HMW-OMP), abstr. B137, p. 189. In Abstracts of the 95th General Meeting of the American Society for Microbiology 1995. American Society for Microbiology, Washington, D.C. |
| 57. |
Verduin, C. M.,
M. Jansze,
C. Hol,
T. E. Mollnes,
J. Verhoef, and H. van Dijk.
1994.
Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation.
Infect. Immun.
62:589-595 |
| 58. | Yang, Y.-P., L. E. Myers, U. Mcguinness, P. Chong, Y. Kwok, M. H. Klein, and R. E. Harkness. 1997. The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol. Med. Microbiol. 17:187-199[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»